Glass Industry News

SCHOTT Pharma delivers right after IPO with strong profitable growth for the full year, at the upper end of its guidance

, SCHOTT

Successful fiscal year 2023, with a year-on-year increase in revenues of 9% to EUR 899m supported by increased share of revenue from strong-margin high-value solutions

Strong EBITDA increase of 9% to EUR 239m leads to an EBITDA margin of 26.6%

Full set of FY 2023 financial results to be published on January 26, 2024

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, closed its fiscal year 2023¹ with revenues of EUR 899m at the upper end of its guidance. Compared to EUR 821m in FY 2022, this represents a strong increase of 9%, taking into account the effects of customers’ temporary destocking in the core vials product category during the year. The company’s EBITDA increased in line with revenue to EUR 239m (+9% yoy), enabling SCHOTT Pharma to maintain its high EBITDA margin of 26.6%. The strong growth was enabled by the expansion of SCHOTT Pharma’s production capacities, especially for drug delivery systems and the new production lines for prefillable polymer syringes in Müllheim, Germany. This key milestone was also a key contributor to the share of revenue from strong-margin high-value solutions increasing by 9 percentage points to 48%, which was better than expected.

“We are very pleased that we were able to fully deliver on our promises and meet our growth targets that we set out during our recent IPO. Our strong growth and high level of profitability not only continue to demonstrate our attractive financial profile, but also confirm our strategic focus on pharma trends and the fast-growing market for high-value solutions. For those reasons, we are confident about both the coming financial year and our mid-term targets”, said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma. The strong performance of high-value solutions (HVS) drove impressive overall growth despite the effects of underutilization in the core vials product category from customer destocking in the second half of the financial year.

With its products, SCHOTT Pharma serves some of the most important and exciting pharma trends, such as GLP-1, homecare and mRNA, that will continue to serve as growth drivers. The company continuously develops solutions for new drug categories to ensure their safe storage and administration to patients all over the world.

As of December 18, 2023, SCHOTT Pharma was included in the SDAX, joining the DAX family for the first time.

SCHOTT Pharma will publish its 2023 annual report including the non-financial report on January 26, 2024.
 

, © SCHOTT

News material on the Site is copyright and belongs to the Company or to its third party news provider, and all rights are reserved. Any User who accesses such material may do so only for its own personal use, and the use of such material is at the sole risk of the User. Redistribution or other commercial exploitation of such news material is expressly prohibited. Where such news material is provided by a third party, each User agrees to observe and be bound by the specific terms of use applying to such news material. We do not represent or endorse the accuracy or reliability of any of the info contained in any news or external websites referred to in the news.

Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.



Info Grid

Glass studies

Updated worldwide glass study 2024

plants.glassglobal.com

Updated hollow glass study 2024

Request more information

Updated float glass study 2024

Request more information

Further glass market studies

Request more information

Company Profile



Updated worldwide glass market study 2024 available now for flat, container glass and tableware

We have updated our international studies on flat glass, container glass and tableware for 2024.

This unique software provides a global overview about glass producers and technical details. Easy to use and clear tables summarize information and data about glass makers such as: Glass types: flat glass, container glass, tableware, production capacities in regions and countries, number of furnaces, furnace types, year of construction, glass types and sub-types, products, project information, special news and downloads.

Further databases supplying demoscopic data and import and export data complete the market survey. Based on these data, prepare individual country profiles with information about local production capacities, local market sizes and expected demand in the future.

Request your offer via plants.glassglobal.com.

Updated container glass study 2024

X

Updated float glass study 2024

X

Further glass studies and reports 2024

X